Ingevity (NYSE:NGVT) Stock Price Target Lowered at BMO Capital Markets

Ingevity logo with Materials background
Image from MarketBeat Media, LLC.

Key Points

  • BMO Capital Markets lowered Ingevity’s price target from $85 to $72 but maintained an “outperform” rating, implying 32% upside from the share price cited in the report.
  • Analyst views are mixed: Ingevity has an average “Hold” rating and a consensus price target of $76.33, with two Buy ratings and three Hold ratings.
  • Ingevity beat quarterly expectations, reporting EPS of $1.63 versus a $1.56 consensus and revenue of $305.1 million versus $303.91 million expected.
  • MarketBeat previews the top five stocks to own by December 1st.

Ingevity (NYSE:NGVT - Get Free Report) had its price objective lowered by analysts at BMO Capital Markets from $85.00 to $72.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. BMO Capital Markets's price objective would indicate a potential upside of 32.01% from the company's current price.

Several other research firms also recently weighed in on NGVT. Wall Street Zen downgraded Ingevity from a "buy" rating to a "hold" rating in a research report on Saturday, November 7th. Weiss Ratings upgraded Ingevity from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, November 4th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Ingevity presently has an average rating of "Hold" and an average price target of $76.33.

Check Out Our Latest Research Report on NGVT

Ingevity Price Performance

Shares of NYSE NGVT traded down $1.42 during trading on Friday, hitting $54.54. The company had a trading volume of 60,270 shares, compared to its average volume of 294,709. The stock has a fifty day simple moving average of $68.85 and a two-hundred day simple moving average of $70.93. Ingevity has a fifty-two week low of $48.00 and a fifty-two week high of $79.29. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 32.12 and a beta of 1.12. The company has a quick ratio of 1.05, a current ratio of 1.48 and a debt-to-equity ratio of 15.70.

Ingevity (NYSE:NGVT - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.56 by $0.07. The business had revenue of $305.10 million during the quarter, compared to analysts' expectations of $303.91 million. Ingevity had a net margin of 5.28% and a return on equity of 405.38%. On average, research analysts expect that Ingevity will post 5.40 earnings per share for the current year.

Institutional Trading of Ingevity

Hedge funds have recently bought and sold shares of the business. Canada Pension Plan Investment Board acquired a new stake in Ingevity during the second quarter worth about $1,113,000. The Manufacturers Life Insurance Company acquired a new position in Ingevity in the 2nd quarter valued at about $1,305,000. Hsbc Holdings PLC acquired a new position in Ingevity in the 2nd quarter valued at about $1,568,000. Bank of New York Mellon Corp acquired a new position in Ingevity in the 2nd quarter valued at about $16,035,000. Finally, Dayah Capital LLC purchased a new stake in shares of Ingevity in the 2nd quarter valued at approximately $3,590,000. Institutional investors and hedge funds own 91.59% of the company's stock.

Ingevity Company Profile

(Get Free Report)

Ingevity is a specialty chemicals and materials company headquartered in North Charleston, South Carolina. It develops and manufactures high-performance activated carbon and specialty chemical products for industrial and consumer applications. Its activated carbon products are used in vehicle fuel-vapor emission control and other applications. The company also makes specialty chemicals and polymer materials used in areas such as pavement technologies, coatings, adhesives and elastomers. Ingevity serves customers in markets around the world.

Further Reading

Analyst Recommendations for Ingevity (NYSE:NGVT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ingevity Right Now?

Before you consider Ingevity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.

While Ingevity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines